Jazz Pharmaceuticals (JAZZ) Amortization - Intangibles (2010 - 2026)

Jazz Pharmaceuticals' Amortization - Intangibles history runs 17 years deep, the most recent figure standing at $172.3 million for Q1 2026.

• On a quarterly basis, Amortization - Intangibles rose 11.59% year-over-year to $172.3 million in Q1 2026; TTM through Mar 2026 was $672.5 million, a 7.43% increase from a year earlier, with the FY2025 full-year figure at $654.7 million, up 4.36% from the prior year.
• Amortization - Intangibles rose to $172.3 million in Q1 2026 per JAZZ's latest filing, from $169.7 million in the prior quarter.
• Across five years, Amortization - Intangibles topped out at $172.3 million in Q1 2026 and bottomed at $137.4 million in Q4 2022.
• The 5-year median for Amortization - Intangibles is $155.2 million (2024), against an average of $156.6 million.
• Across the five-year window, Amortization - Intangibles jumped 152.37% in 2022 and decreased 12.96% in 2023, its largest moves.
• Year by year, Amortization - Intangibles stood at $137.4 million in 2022, then rose by 10.31% to $151.6 million in 2023, then grew by 4.85% to $158.9 million in 2024, then increased by 6.82% to $169.7 million in 2025, then advanced by 1.51% to $172.3 million in 2026.
• Per Business Quant, the three latest JAZZ Amortization - Intangibles figures stand at $172.3 million (Q1 2026), $169.7 million (Q4 2025), and $168.4 million (Q3 2025).